516 related articles for article (PubMed ID: 16357187)
1. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis.
Sinha P; Clements VK; Ostrand-Rosenberg S
Cancer Res; 2005 Dec; 65(24):11743-51. PubMed ID: 16357187
[TBL] [Abstract][Full Text] [Related]
2. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.
Sinha P; Clements VK; Ostrand-Rosenberg S
J Immunol; 2005 Jan; 174(2):636-45. PubMed ID: 15634881
[TBL] [Abstract][Full Text] [Related]
3. Stat 6-dependent induction of myeloid derived suppressor cells after physical injury regulates nitric oxide response to endotoxin.
Munera V; Popovic PJ; Bryk J; Pribis J; Caba D; Matta BM; Zenati M; Ochoa JB
Ann Surg; 2010 Jan; 251(1):120-6. PubMed ID: 20032720
[TBL] [Abstract][Full Text] [Related]
4. Myeloid suppressor cell-associated immune dysfunction in CSA1M fibrosarcoma tumor-bearing mice.
Zhou R; He PL; Ren YX; Wang WH; Zhou RY; Wan H; Ono S; Fujiwara H; Zuo JP
Cancer Sci; 2007 Jun; 98(6):882-9. PubMed ID: 17433038
[TBL] [Abstract][Full Text] [Related]
5. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection.
Tsung K; Dolan JP; Tsung YL; Norton JA
Cancer Res; 2002 Sep; 62(17):5069-75. PubMed ID: 12208763
[TBL] [Abstract][Full Text] [Related]
6. IL-11-induced reduction of C/EBP transcription factor binding may contribute to the IL-12 downregulation in tumor-bearing mice.
Torroella-Kouri M; Keith JC; Ivanova M; Lopez DM
Int J Oncol; 2003 Feb; 22(2):439-48. PubMed ID: 12527946
[TBL] [Abstract][Full Text] [Related]
7. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.
Donkor MK; Lahue E; Hoke TA; Shafer LR; Coskun U; Solheim JC; Gulen D; Bishay J; Talmadge JE
Int Immunopharmacol; 2009 Jul; 9(7-8):937-48. PubMed ID: 19362167
[TBL] [Abstract][Full Text] [Related]
8. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression.
Sinha P; Clements VK; Miller S; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2005 Nov; 54(11):1137-42. PubMed ID: 15877228
[TBL] [Abstract][Full Text] [Related]
9. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.
Zea AH; Rodriguez PC; Atkins MB; Hernandez C; Signoretti S; Zabaleta J; McDermott D; Quiceno D; Youmans A; O'Neill A; Mier J; Ochoa AC
Cancer Res; 2005 Apr; 65(8):3044-8. PubMed ID: 15833831
[TBL] [Abstract][Full Text] [Related]
10. Myeloid suppressor cells regulate the lung environment--letter.
Bosiljcic M; Hamilton MJ; Banath JP; Lepard NE; McDougal DC; Jia JX; Krystal G; Bennewith KL
Cancer Res; 2011 Jul; 71(14):5050-1; author reply 5052-3. PubMed ID: 21750177
[TBL] [Abstract][Full Text] [Related]
11. Interferon-gamma-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma.
Pulaski BA; Smyth MJ; Ostrand-Rosenberg S
Cancer Res; 2002 Aug; 62(15):4406-12. PubMed ID: 12154047
[TBL] [Abstract][Full Text] [Related]
12. Transmembrane TNF-α promotes suppressive activities of myeloid-derived suppressor cells via TNFR2.
Hu X; Li B; Li X; Zhao X; Wan L; Lin G; Yu M; Wang J; Jiang X; Feng W; Qin Z; Yin B; Li Z
J Immunol; 2014 Feb; 192(3):1320-31. PubMed ID: 24379122
[TBL] [Abstract][Full Text] [Related]
13. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent.
Ostrand-Rosenberg S; Clements VK; Terabe M; Park JM; Berzofsky JA; Dissanayake SK
J Immunol; 2002 Nov; 169(10):5796-804. PubMed ID: 12421960
[TBL] [Abstract][Full Text] [Related]
14. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.
Nonaka K; Saio M; Suwa T; Frey AB; Umemura N; Imai H; Ouyang GF; Osada S; Balazs M; Adany R; Kawaguchi Y; Yoshida K; Takami T
J Leukoc Biol; 2008 Sep; 84(3):679-88. PubMed ID: 18566103
[TBL] [Abstract][Full Text] [Related]
15. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway.
Terabe M; Matsui S; Noben-Trauth N; Chen H; Watson C; Donaldson DD; Carbone DP; Paul WE; Berzofsky JA
Nat Immunol; 2000 Dec; 1(6):515-20. PubMed ID: 11101874
[TBL] [Abstract][Full Text] [Related]
16. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.
Sinha P; Clements VK; Fulton AM; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4507-13. PubMed ID: 17483367
[TBL] [Abstract][Full Text] [Related]
17. Macrophages are more potent immune suppressors ex vivo than immature myeloid-derived suppressor cells induced by metastatic murine mammary carcinomas.
Hamilton MJ; Bosiljcic M; Lepard NE; Halvorsen EC; Ho VW; Banáth JP; Krystal G; Bennewith KL
J Immunol; 2014 Jan; 192(1):512-22. PubMed ID: 24285836
[TBL] [Abstract][Full Text] [Related]
18. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.
Marigo I; Dolcetti L; Serafini P; Zanovello P; Bronte V
Immunol Rev; 2008 Apr; 222():162-79. PubMed ID: 18364001
[TBL] [Abstract][Full Text] [Related]
19. Tumor- and organ-dependent infiltration by myeloid-derived suppressor cells.
Younos I; Donkor M; Hoke T; Dafferner A; Samson H; Westphal S; Talmadge J
Int Immunopharmacol; 2011 Jul; 11(7):816-26. PubMed ID: 21376153
[TBL] [Abstract][Full Text] [Related]
20. Tumor-associated macrophages of mouse mammary tumors. I. Differential cytotoxicity of macrophages from metastatic and nonmetastatic tumors.
Loveless SE; Heppner GH
J Immunol; 1983 Oct; 131(4):2074-8. PubMed ID: 6619548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
